Joshua Lin and Team: New Evidence on Long-Term Anticoagulation for Unprovoked VTE
Joshua Lin, Executive Director of Mass General Brigham Center for Integrated Healthcare Data Research, posted on LinkedIn:
”New Evidence on Long-Term Anticoagulation for Unprovoked VTE
We are pleased to share our recent BMJ publication demonstrating that continuation of oral anticoagulant therapy beyond the initial 90-day treatment period after a first unprovoked venous thromboembolism (VTE) is associated with a significantly lower risk of recurrent thrombosis and all-cause mortality, compared with early discontinuation. Extended therapy, however, is also associated with a higher risk of major bleeding – underscoring the importance of individualized clinical decision-making.
Full study here.
Press Release here.”
Title: Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulation
Authors: Kueiyu Joshua Lin, Dae Hyun Kim, Daniel E Singer, Yichi Zhang, Alexander Cervone, Anna R Kehoe, Katsiaryna Bykov
Stay updated with Hemostasis Today.
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads
-
Aug 30, 2026, 16:18Tushar Namdeo: Platelets in Different Diseases
-
Aug 30, 2026, 16:16Fatima Zafar: Anaemia – Why This “Common” Condition Should Never Be Ignored
-
Aug 30, 2026, 16:13Umeshkumar C.: Evaluating Scoring Systems and Biomarkers for DIC in Critically Ill Patients